Kevin Gorman | Chief Executive Officer |
Jane Sorensen | Head-Investor Relations |
Matt Abernethy | Chief Financial Officer |
Eric Benevich | Chief Commercial Officer |
Chris OBrien | Special Consultant-Neurocrine |
Eiry Roberts | Chief Medical Officer |
Geoff Meacham | Barclays |
Tazeen Ahmad | Bank of America |
Anupam Rama | JP Morgan |
Jeffrey Lin | Leerink |
Brian Skorney | Robert W. Baird |
Philip Nadeau | Cowen and Company |
Biren Amin | Jefferies |
Charles Duncan | Piper Jaffray |
Andrew Peters | Deutsche Bank |
Jay Olson | Oppenheimer |
Good day, everyone, and welcome to Neurocrine Biosciences’ Reports Fourth Quarter and Year End 2017 Results. [Operator Instructions] Please note, today's call is being recorded. [Operator Instructions] It is now my pleasure to turn the conference over to Kevin Gorman, CEO. Please go ahead, Sir.
Thank you very much, and welcome, everyone, to our fourth quarter earnings call.